Civic Intelligence

Phare Bio Inc.

990EZ • Fiscal year 2020 • EIN 85-1085804

Jul 01, 2019 to Jun 30, 2020 • Filed on Aug 12, 2020

303 Congress St 2nd FLBoston, MA 02210

(617) 426-5900

Siviq Scores

Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.

Liabilities / Assets

55th percentile

0.00x

Tied with the lowest-debt nonprofits in its peer group.

2020 filings • 501(c)3 • <$500k nonprofits • Source year 2020

Liabilities / Revenue

Score unavailable

No value available

Liabilities-to-revenue requires both liabilities and revenue on this filing.

Source year 2020

Net Margin

Score unavailable

No value available

Net margin requires both revenue and expenses on this filing.

Source year 2020

Top Officer Pay

76th percentile

$0

Higher top officer pay than 76% of similar nonprofits.

2020 filings • 501(c)3 • <$500k nonprofits • Source year 2020

Asset Growth

44th percentile

0.0%

Faster asset growth than 44% of similar nonprofits.

2020 filings • 501(c)3 • <$500k nonprofits • Annualized from 2019 to 2020

Revenue Growth

Score unavailable

No value available

A valid growth rate could not be computed from the available filing history.

Annualized from 2019 to 2020

Assets

Flat

$1

Flat from 2019

Net Assets

$0

No earlier filing loaded for comparison.

Liabilities

Flat

$0

Flat from 2019

Revenue

Flat

$0

Flat from 2019

Expenses

Flat

$0

Flat from 2019

Net Income

Flat

$0

Flat from 2019

Historical Trend

Balance Sheet Trend

The highlighted filing sits inside the broader history for assets, liabilities, and net assets.

$3.0M$2.0M$1.0M$0Assets 2019: $1Liabilities 2019: $02019Assets 2020: $1Liabilities 2020: $0Net Assets 2020: $02020Assets 2021: $632,271Liabilities 2021: $28,461Net Assets 2021: $603,8102021Assets 2022: $1,009,435Liabilities 2022: $25,465Net Assets 2022: $983,9702022Assets 2023: $1,837,494Liabilities 2023: $88,135Net Assets 2023: $1,749,3592023Assets 2024: $2,586,256Liabilities 2024: $76,903Net Assets 2024: $2,509,3532024

Highlighted filing

2020

Assets$1
Liabilities$0
Net Assets$0

Operations Trend

Revenue, expenses, and net income across loaded years, with this filing highlighted.

$3.0M$2.0M$1.0M$0Revenue 2019: $0Expenses 2019: $0Net Income 2019: $02019Revenue 2020: $0Expenses 2020: $0Net Income 2020: $02020Revenue 2021: $1,057,242Expenses 2021: $453,432Net Income 2021: $603,8102021Revenue 2022: $1,558,823Expenses 2022: $1,178,664Net Income 2022: $380,1592022Revenue 2023: $2,009,513Expenses 2023: $1,249,510Net Income 2023: $760,0032023Revenue 2024: $2,148,132Expenses 2024: $1,461,003Net Income 2024: $687,1292024

Highlighted filing

2020

Revenue$0
Expenses$0
Net Income$0
Jump To
Filing Snapshot
Filing Period
Jul 1, 2019 to Jun 30, 2020
Signed
Aug 12, 2020
Return Version
2019v5.0
Mission and Program Overview

Mission

Non profit bio tech research

Phare bio's mission is to develop critically needed antibiotics to address a looming crisis in antibiotic resistance. Using novel ai and deep learning approaches, phare bio aims to rapidly discover and develop new classes of antibiotics against the deadliest pathogens, and ensure that these therapies reach the patients in greatest need.

Program Services

DescriptionGrantsExpenses
N/A--
Compensation and Service Providers

Employees

NameTitleFull / Part TimeBaseOtherTotal
AKHILA KOSARAJUCEO-$0--
Filing and Contact Details

Filer

Filer Name
Phare Bio Inc
EIN
85-1085804
Phone
6174265900
Address
303 CONGRESS ST 2ND FL, BOSTON, MA 02210

Signing Officer

Name
Akhila Kosaraju
Title
CEO
Phone
6174265900
Signed
2020-08-12

Preparer

Firm
Early Growth Financial Services
Address
2345 YALE ST 1ST FL, PALO ALTO, CA 94306
Preparer
Anjum Tunuli
Phone
4152343437
Supplemental Narrative

Additional Explanations

Form 990-ez, Page 1, Item B

The original tax return was reported on the wrong tax year 990. The mission statement is included.

Form 990-ez, Part III

Phare bio's mission is to develop critically needed antibiotics to address a looming crisis in antibiotic resistance. Using novel ai and deep learning approaches, phare bio aims to rapidly discover and develop new classes of antibiotics against the deadliest pathogens, and ensure that these therapies reach the patients in greatest need.

Raw XML Appendix83 raw XML fields

This appendix keeps the raw XML leaves available for debugging and edge-case review. The human report above is the primary experience.

Path#Value
IRS990EZ/ActivitiesNotPreviouslyRptInd0false
IRS990EZ/AmendedReturnInd0X
IRS990EZ/BooksInCareOfDetail/PersonNm0AKHILA KOSARAJU
IRS990EZ/BooksInCareOfDetail/PhoneNum06502706137
IRS990EZ/BooksInCareOfDetail/USAddress/AddressLine1Txt0303 CONGRESS ST 2ND FL
IRS990EZ/BooksInCareOfDetail/USAddress/CityNm0BOSTON
IRS990EZ/BooksInCareOfDetail/USAddress/StateAbbreviationCd0MA
IRS990EZ/BooksInCareOfDetail/USAddress/ZIPCd002210
IRS990EZ/ChgMadeToOrgnzngDocNotRptInd0false
IRS990EZ/DonorAdvisedFndsInd0false
IRS990EZ/EngagedInExcessBenefitTransInd0false
IRS990EZ/FiledScheduleAInd0true
IRS990EZ/ForeignFinancialAccountInd0false
IRS990EZ/ForeignOfficeInd0false
IRS990EZ/Form1120PolFiledInd0false
IRS990EZ/Form990TotalAssetsGrp/BOYAmt00
IRS990EZ/Form990TotalAssetsGrp/EOYAmt00
IRS990EZ/InfoInScheduleOPartIIIInd0X
IRS990EZ/InitialReturnInd0X
IRS990EZ/LobbyingActivitiesInd0false
IRS990EZ/MadeLoansToFromOfficersInd0false
IRS990EZ/MethodOfAccountingAccrualInd0X
IRS990EZ/NetAssetsOrFundBalancesGrp/BOYAmt00
IRS990EZ/NetAssetsOrFundBalancesGrp/EOYAmt00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt0000.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm0AKHILA KOSARAJU
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt0CEO
IRS990EZ/OperateHospitalInd0false
IRS990EZ/Organization501c3Ind0X
IRS990EZ/OrganizationDissolvedEtcInd0false
IRS990EZ/OrganizationHadUBIInd0false
IRS990EZ/PartVIHghstPdCntrctProfSrvcTxt0NONE
IRS990EZ/PartVIOfCompOfHghstPdEmplTxt0NONE
IRS990EZ/PoliticalCampaignActyInd0false
IRS990EZ/PrimaryExemptPurposeTxt0PHARE BIO'S MISSION IS TO DEVELOP CRITICALLY NEEDED ANTIBIOTICS TO ADDRESS A LOOMING CRISIS IN ANTIBIOTIC RESISTANCE. USING NOVEL AI AND DEEP LEARNING APPROACHES, PHARE BIO AIMS TO RAPIDLY DISCOVER AND DEVELOP NEW CLASSES OF ANTIBIOTICS AGAINST THE DEADLIEST PATHOGENS, AND ENSURE THAT THESE THERAPIES REACH THE PATIENTS IN GREATEST NEED.
IRS990EZ/ProgramSrvcAccomplishmentGrp/DescriptionProgramSrvcAccomTxt0N/A
IRS990EZ/ProhibitedTaxShelterTransInd0false
IRS990EZ/RelatedOrganizationCtrlEntInd0false
IRS990EZ/ScheduleBNotRequiredInd0X
IRS990EZ/SchoolOperatingInd0false
IRS990EZ/SubjectToProxyTaxInd0false
IRS990EZ/TanningServicesProvidedInd0false
IRS990EZ/TransactionWithControlEntInd0false
IRS990EZ/TrnsfrExmptNonChrtblRltdOrgInd0false
IRS990EZ/TypeOfOrganizationOtherDesc0NON PROFIT
IRS990EZ/TypeOfOrganizationOtherInd0X
IRS990EZ/WebsiteAddressTxt0PHAREBIO.ORG
IRS990ScheduleA/First5Years170Ind0X
IRS990ScheduleA/PublicOrganization170Ind0X
IRS990ScheduleA/PublicSupportTotal170Amt01
IRS990ScheduleA/SubstantialContributorsTotAmt01
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt0THE ORIGINAL TAX RETURN WAS REPORTED ON THE WRONG TAX YEAR 990. THE MISSION STATEMENT IS INCLUDED.
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt1PHARE BIO'S MISSION IS TO DEVELOP CRITICALLY NEEDED ANTIBIOTICS TO ADDRESS A LOOMING CRISIS IN ANTIBIOTIC RESISTANCE. USING NOVEL AI AND DEEP LEARNING APPROACHES, PHARE BIO AIMS TO RAPIDLY DISCOVER AND DEVELOP NEW CLASSES OF ANTIBIOTICS AGAINST THE DEADLIEST PATHOGENS, AND ENSURE THAT THESE THERAPIES REACH THE PATIENTS IN GREATEST NEED.
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc0FORM 990-EZ, PAGE 1, ITEM B
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc1FORM 990-EZ, PART III
ReturnHeader/BuildTS02022-09-23 18:48:47Z
ReturnHeader/BusinessOfficerGrp/PersonNm0AKHILA KOSARAJU
ReturnHeader/BusinessOfficerGrp/PersonTitleTxt0CEO
ReturnHeader/BusinessOfficerGrp/PhoneNum06174265900
ReturnHeader/BusinessOfficerGrp/SignatureDt02020-08-12
ReturnHeader/Filer/BusinessName/BusinessNameLine1Txt0PHARE BIO INC
ReturnHeader/Filer/BusinessNameControlTxt0PHAR
ReturnHeader/Filer/EIN0851085804
ReturnHeader/Filer/PhoneNum06174265900
ReturnHeader/Filer/USAddress/AddressLine1Txt0303 CONGRESS ST 2ND FL
ReturnHeader/Filer/USAddress/CityNm0BOSTON
ReturnHeader/Filer/USAddress/StateAbbreviationCd0MA
ReturnHeader/Filer/USAddress/ZIPCd002210
ReturnHeader/PreparerFirmGrp/PreparerFirmEIN0264150644
ReturnHeader/PreparerFirmGrp/PreparerFirmName/BusinessNameLine1Txt0EARLY GROWTH FINANCIAL SERVICES
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/AddressLine1Txt02345 YALE ST 1ST FL
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/CityNm0PALO ALTO
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/StateAbbreviationCd0CA
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/ZIPCd094306
ReturnHeader/PreparerPersonGrp/PhoneNum04152343437
ReturnHeader/PreparerPersonGrp/PreparationDt02022-08-26
ReturnHeader/PreparerPersonGrp/PreparerPersonNm0ANJUM TUNULI
ReturnHeader/ReturnTs02022-08-26T20:48:39-04:00
ReturnHeader/ReturnTypeCd0990EZ
ReturnHeader/TaxPeriodBeginDt02020-04-29
ReturnHeader/TaxPeriodEndDt02020-06-30
ReturnHeader/TaxYr02019

Document Assets

No mirrored PDF or thumbnail assets are attached yet.

Filings